Search

Your search keyword '"Injections, Subcutaneou"' showing total 38 results

Search Constraints

Start Over You searched for: Descriptor "Injections, Subcutaneou" Remove constraint Descriptor: "Injections, Subcutaneou" Topic human Remove constraint Topic: human
38 results on '"Injections, Subcutaneou"'

Search Results

1. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

2. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

3. Ofatumumab versus Teriflunomide in Multiple Sclerosis

4. Improvement of treatment adherence with growth hormone by easypod™ device: experience of an Italian centre

5. Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis

6. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study

7. Long-term glycemic control and glucose variability assessed with continuous glucose monitoring in a pediatric population with type 1 diabetes: Determination of optimal sampling duration

8. Efficacy and rapid activity of omalizumab retreatment in chronic spontaneous urticaria

9. Dupilumab and alopecia: A Janus effect

10. Vedolizumab versus Adalimumab for moderate-to-severe ulcerative colitis

11. Research Techniques Made Simple: Skin Carcinogenesis Models: Xenotransplantation Techniques

12. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

13. Skin complications of insulin injections: A case presentation and a possible explanation of hypoglycaemia

14. Subcutaneous interferon ß-1a in the treatment of clinically isolated syndromes:3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study

15. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies

16. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

17. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

18. Therapeutic use of hyaluronic acid fillers in the treatment of corticosteroid-induced skin and subcutaneous atrophy

19. Skin Necrosis Following Adipocitolitic Solution Injections

20. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

21. A CE-marked drug used for localized adiposity reduction: A 4-year experience

22. How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis

23. Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study

24. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series

25. Refractory rheumatoid factor positive polyarthritis in a female adolescent already suffering from type 1 diabetes mellitus and Hashimoto's thyroiditis successfully treated with etanercept

26. Occurrence and extent of bruising according to duration of administration of subcutaneous Low-Molecular-Weight Heparin: a quasi-experimental case-crossover study

27. Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia

28. Effects of lanreotide autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: A 1-year prospective multicenter study

29. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia

30. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease

31. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients

32. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy

33. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study

34. Effects of recombinant human insulin-like growth factor I administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in anorexia nervosa

35. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma

36. Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study

37. Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant

38. Adalimumab versus Rifampicin Plus Clindamycin for the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Retrospective Study

Catalog

Books, media, physical & digital resources